What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “subcutaneous injection(s) with PHIN-214 terlipressin derivative”In the company’s words, NCT05490888 on ClinicalTrials.gov
- Tested for
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Main trialPhase 1
- “This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.”In the company’s words, NCT05490888 on ClinicalTrials.gov
- Other names
- Terlipressin derivative
Other drugs for Cirrhosis, Liver
- ElafibranorIpsen · Phase 3
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- HydronidoneBeijing Continent Pharmaceutical Co, Ltd. · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 May 2026 | Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026